Acura Pharmaceuticals, Inc. (ACUR)
OTCMKTS
· Delayed Price · Currency is USD
0.0023
0.00 (0.00%)
Dec 3, 2024, 3:00 PM EST
Acura Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | 2016 - 2012 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '21 Dec 31, 2021 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | 2016 - 2012 |
| Revenue | 1.56 | 1.56 | 3.57 | 2.66 | 0.41 | 2.97 | Upgrade
|
| Revenue Growth (YoY) | -56.22% | -56.22% | 34.36% | 548.05% | -86.18% | -33.56% | Upgrade
|
| Cost of Revenue | 1.52 | 1.52 | 1.78 | 1.51 | 1.76 | 3.85 | Upgrade
|
| Gross Profit | 0.04 | 0.04 | 1.79 | 1.15 | -1.35 | -0.88 | Upgrade
|
| Selling, General & Admin | 1.25 | 1.25 | 1.88 | 1.88 | 2.57 | 4.34 | Upgrade
|
| Operating Expenses | 1.25 | 1.25 | 1.88 | 1.88 | 2.57 | 4.34 | Upgrade
|
| Operating Income | -1.21 | -1.21 | -0.09 | -0.73 | -3.92 | -5.23 | Upgrade
|
| Interest Expense | -0.2 | -0.2 | -0.45 | -0.46 | -0.4 | -0.6 | Upgrade
|
| Interest & Investment Income | - | - | - | 0.01 | 0.17 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -1.41 | -1.41 | -0.54 | -1.17 | -4.14 | -5.82 | Upgrade
|
| Asset Writedown | - | - | -0.67 | - | - | - | Upgrade
|
| Other Unusual Items | 0.54 | 0.54 | - | -2.6 | 0.3 | - | Upgrade
|
| Pretax Income | -0.88 | -0.88 | -1.21 | -3.77 | -3.84 | -5.82 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | -0.14 | Upgrade
|
| Net Income | -0.88 | -0.88 | -1.21 | -3.77 | -3.84 | -5.68 | Upgrade
|
| Net Income to Common | -0.88 | -0.88 | -1.21 | -3.77 | -3.84 | -5.68 | Upgrade
|
| Shares Outstanding (Basic) | 57 | 57 | 32 | 27 | 21 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 57 | 57 | 32 | 27 | 21 | 16 | Upgrade
|
| Shares Change (YoY) | 75.75% | 75.75% | 20.96% | 26.36% | 32.97% | 33.98% | Upgrade
|
| EPS (Basic) | -0.02 | -0.02 | -0.04 | -0.14 | -0.18 | -0.36 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.02 | -0.04 | -0.14 | -0.18 | -0.36 | Upgrade
|
| Free Cash Flow | -0.74 | -0.74 | -0.72 | -0.62 | -3.91 | -4.51 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.02 | -0.02 | -0.18 | -0.28 | Upgrade
|
| Gross Margin | 2.50% | 2.50% | 50.11% | 43.36% | - | -29.77% | Upgrade
|
| Operating Margin | -77.67% | -77.67% | -2.52% | -27.29% | -954.88% | -176.16% | Upgrade
|
| Profit Margin | -56.24% | -56.24% | -33.84% | -142.04% | -937.07% | -191.57% | Upgrade
|
| Free Cash Flow Margin | -47.47% | -47.47% | -20.14% | -23.26% | -953.17% | -152.06% | Upgrade
|
| EBITDA | -1.14 | -1.14 | 0.04 | -0.45 | -3.64 | -4.93 | Upgrade
|
| EBITDA Margin | -73.00% | -73.00% | 0.98% | -17.01% | - | -166.25% | Upgrade
|
| D&A For EBITDA | 0.07 | 0.07 | 0.13 | 0.27 | 0.28 | 0.29 | Upgrade
|
| EBIT | -1.21 | -1.21 | -0.09 | -0.73 | -3.92 | -5.23 | Upgrade
|
| EBIT Margin | -77.67% | -77.67% | -2.52% | -27.29% | - | -176.16% | Upgrade
|
| Revenue as Reported | 1.56 | 1.56 | 3.57 | 2.66 | 0.41 | 2.97 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.